DSGN vs. CTNM, PYXS, IMMP, TSVT, NKTR, ENTA, CTMX, XERS, XBIT, and RAPT
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Contineum Therapeutics (CTNM), Pyxis Oncology (PYXS), Immutep (IMMP), 2seventy bio (TSVT), Nektar Therapeutics (NKTR), Enanta Pharmaceuticals (ENTA), CytomX Therapeutics (CTMX), Xeris Biopharma (XERS), XBiotech (XBIT), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Contineum Therapeutics (NASDAQ:CTNM) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
Design Therapeutics received 7 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 34.48% of users gave Design Therapeutics an outperform vote.
In the previous week, Design Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Design Therapeutics and 3 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.89 beat Design Therapeutics' score of -0.28 indicating that Design Therapeutics is being referred to more favorably in the news media.
Design Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity.
Contineum Therapeutics currently has a consensus price target of $28.00, suggesting a potential upside of 80.65%. Design Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 49.66%. Given Design Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Contineum Therapeutics is more favorable than Design Therapeutics.
56.6% of Design Therapeutics shares are held by institutional investors. 27.8% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Contineum Therapeutics beats Design Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
